Stock Analysis on Net
Stock Analysis on Net

Medtronic PLC (NYSE:MDT)

Analysis of Profitability Ratios

Microsoft Excel

Profitability Ratios (Summary)

Return on Sales

Return on Investment

Medtronic PLC, profitability ratios

Microsoft Excel
Apr 24, 2026 Apr 25, 2025 Apr 26, 2024 Apr 28, 2023 Apr 29, 2022 Apr 30, 2021
Return on Sales
Gross profit margin 65.02% 65.32% 65.34% 65.67% 67.98% 65.19%
Operating profit margin 17.78% 17.76% 15.89% 17.56% 18.15% 14.89%
Net profit margin 13.20% 13.90% 11.36% 12.03% 15.90% 11.97%
Return on Investment
Return on equity (ROE) 9.71% 9.71% 7.32% 7.30% 9.59% 7.01%
Return on assets (ROA) 5.16% 5.09% 4.09% 4.13% 5.54% 3.87%

Based on: 10-K (reporting date: 2026-04-24), 10-K (reporting date: 2025-04-25), 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30).


The profitability metrics exhibit a cyclical trend over the analyzed period, characterized by a peak in performance during the 2022 fiscal year, a subsequent decline through 2024, and a partial recovery leading into 2026.

Gross Profit Margin
A maximum value of 67.98% was recorded in April 2022. Following this peak, the margin experienced a steady, slight contraction, concluding the period at 65.02% in April 2026. This indicates a relative stability in core production costs despite the slight downward trajectory over the final four years.
Operating and Net Profit Margins
Operating profit margins rose significantly to 18.15% in 2022 before declining to a low of 15.89% in 2024, subsequently recovering to 17.78% by 2026. Net profit margins followed a similar volatile pattern, peaking at 15.90% in 2022 and dropping to 11.36% in 2024, before ending the period at 13.20%. The correlation between these two metrics suggests that operational efficiency was the primary driver of net profitability changes.
Return on Equity (ROE) and Return on Assets (ROA)
Both return metrics demonstrate a mirrored progression. ROE climbed from 7.01% in 2021 to 9.59% in 2022, dipped during 2023 and 2024, and reached its highest point of 9.71% in 2025 and 2026. ROA followed this trend, rising from 3.87% in 2021 to 5.54% in 2022, before stabilizing at 5.16% by 2026. The simultaneous recovery of ROE and ROA in the final two years indicates an improvement in the efficiency of both asset utilization and shareholder equity returns.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Gross Profit Margin

Medtronic PLC, gross profit margin calculation, comparison to benchmarks

Microsoft Excel
Apr 24, 2026 Apr 25, 2025 Apr 26, 2024 Apr 28, 2023 Apr 29, 2022 Apr 30, 2021
Selected Financial Data (US$ in millions)
Gross profit 23,643 21,905 21,148 20,508 21,541 19,634
Net sales 36,364 33,537 32,364 31,227 31,686 30,117
Profitability Ratio
Gross profit margin1 65.02% 65.32% 65.34% 65.67% 67.98% 65.19%
Benchmarks
Gross Profit Margin, Competitors2
Abbott Laboratories — 52.62% 50.93% 50.28% 51.54% 52.21%
Elevance Health Inc. — 14.26% 15.92% 16.79% 16.79% 17.09%
Intuitive Surgical Inc. — 66.00% 67.46% 66.39% 67.44% 69.32%
UnitedHealth Group Inc. — 17.81% 21.31% 23.64% 24.09% 23.60%

Based on: 10-K (reporting date: 2026-04-24), 10-K (reporting date: 2025-04-25), 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30).

1 2026 Calculation
Gross profit margin = 100 × Gross profit ÷ Net sales
= 100 × 23,643 ÷ 36,364 = 65.02%

2 Click competitor name to see calculations.


An analysis of the financial performance between April 30, 2021, and April 24, 2026, reveals a consistent upward trajectory in both net sales and gross profit, despite fluctuations in the gross profit margin.

Revenue and Absolute Profit Growth
Net sales demonstrated steady growth over the six-year period, increasing from 30,117 million USD in 2021 to 36,364 million USD by 2026. Parallel to this, gross profit rose from 19,634 million USD to 23,643 million USD. While a brief contraction in gross profit occurred in 2023, the overall trend indicates a sustained expansion of the top line and absolute gross earnings.
Gross Profit Margin Volatility and Stabilization
The gross profit margin experienced a notable peak in April 2022, reaching 67.98%. Following this peak, a gradual downward correction occurred, with the margin settling into a period of relative stability. From April 2023 to April 2026, the margin remained within a narrow range, fluctuating between 65.02% and 65.67%.
Efficiency Trends
A marginal decline in the gross profit margin is observable from 2022 onward. The decrease from 67.98% in 2022 to 65.02% in 2026 suggests that the cost of goods sold has grown at a slightly faster rate than net sales during this specific interval. However, the maintenance of the margin above the 65% threshold indicates a consistent level of production efficiency and pricing power over the long term.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Operating Profit Margin

Medtronic PLC, operating profit margin calculation, comparison to benchmarks

Microsoft Excel
Apr 24, 2026 Apr 25, 2025 Apr 26, 2024 Apr 28, 2023 Apr 29, 2022 Apr 30, 2021
Selected Financial Data (US$ in millions)
Operating profit 6,467 5,955 5,144 5,485 5,752 4,484
Net sales 36,364 33,537 32,364 31,227 31,686 30,117
Profitability Ratio
Operating profit margin1 17.78% 17.76% 15.89% 17.56% 18.15% 14.89%
Benchmarks
Operating Profit Margin, Competitors2
Abbott Laboratories — 18.17% 16.27% 16.15% 19.16% 19.56%
Elevance Health Inc. — 3.33% 4.16% 4.47% 4.94% 5.15%
Intuitive Surgical Inc. — 29.27% 28.12% 24.80% 25.35% 31.89%
UnitedHealth Group Inc. — 4.27% 8.17% 8.80% 8.83% 8.40%
Operating Profit Margin, Sector
Health Care Equipment & Services — 5.83% 8.25% 8.71% 9.26% 9.13%
Operating Profit Margin, Industry
Health Care — 15.09% 12.50% 12.79% 18.74% 18.04%

Based on: 10-K (reporting date: 2026-04-24), 10-K (reporting date: 2025-04-25), 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30).

1 2026 Calculation
Operating profit margin = 100 × Operating profit ÷ Net sales
= 100 × 6,467 ÷ 36,364 = 17.78%

2 Click competitor name to see calculations.


The financial performance from 2021 to 2026 exhibits a general expansion in both top-line revenue and absolute operating profit, although operational efficiency margins experienced a period of volatility before stabilizing.

Net Sales Performance
Net sales demonstrate a consistent growth trajectory, increasing from 30,117 million US$ in 2021 to 36,364 million US$ by 2026. A marginal contraction occurred in 2023, with sales decreasing slightly to 31,227 million US$, before resuming an upward trend and accelerating significantly between 2025 and 2026.
Operating Profit Trends
Operating profit reflects more volatility than net sales. After a substantial increase from 4,484 million US$ in 2021 to 5,752 million US$ in 2022, a two-year decline followed, reaching a local minimum of 5,144 million US$ in 2024. A strong recovery is evident in the subsequent period, with profit climbing to 6,467 million US$ by 2026.
Operating Profit Margin Analysis
The operating profit margin correlates with the fluctuations in absolute profit. A sharp expansion is noted between 2021 and 2022, where the margin rose from 14.89% to 18.15%. This peak was followed by a steady contraction over the next two years, falling to 15.89% in 2024. Operational efficiency recovered in the final two years, reaching 17.76% in 2025 and remaining nearly flat at 17.78% in 2026, indicating a period of stabilization.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Net Profit Margin

Medtronic PLC, net profit margin calculation, comparison to benchmarks

Microsoft Excel
Apr 24, 2026 Apr 25, 2025 Apr 26, 2024 Apr 28, 2023 Apr 29, 2022 Apr 30, 2021
Selected Financial Data (US$ in millions)
Net income attributable to Medtronic 4,801 4,662 3,676 3,758 5,039 3,606
Net sales 36,364 33,537 32,364 31,227 31,686 30,117
Profitability Ratio
Net profit margin1 13.20% 13.90% 11.36% 12.03% 15.90% 11.97%
Benchmarks
Net Profit Margin, Competitors2
Abbott Laboratories — 14.72% 31.95% 14.27% 15.88% 16.42%
Elevance Health Inc. — 2.87% 3.41% 3.52% 3.87% 4.46%
Intuitive Surgical Inc. — 28.38% 27.81% 25.24% 21.25% 29.85%
UnitedHealth Group Inc. — 2.72% 3.65% 6.09% 6.25% 6.06%
Net Profit Margin, Sector
Health Care Equipment & Services — 4.36% 6.09% 6.43% 7.05% 7.14%
Net Profit Margin, Industry
Health Care — 11.79% 8.84% 11.49% 14.65% 15.24%

Based on: 10-K (reporting date: 2026-04-24), 10-K (reporting date: 2025-04-25), 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30).

1 2026 Calculation
Net profit margin = 100 × Net income attributable to Medtronic ÷ Net sales
= 100 × 4,801 ÷ 36,364 = 13.20%

2 Click competitor name to see calculations.


The analysis of profitability metrics reveals a period of volatility in net profit margins, characterized by a significant peak in 2022 followed by a contraction and a subsequent recovery phase. While net sales demonstrate a consistent long-term upward trajectory, net income has fluctuated, indicating that revenue growth has not translated into a linear increase in profitability.

Net Profit Margin Trends
The net profit margin reached a peak of 15.90% in 2022, representing the highest level of efficiency in converting sales into profit during the period. This was followed by a two-year decline, with the margin dropping to 12.03% in 2023 and reaching a period low of 11.36% in 2024. A recovery is observed starting in 2025, where the margin rose to 13.90%, before slightly moderating to 13.20% in 2026.
Revenue and Income Correlation
Net sales show a steady growth pattern, increasing from 30,117 million USD in 2021 to 36,364 million USD by 2026. However, net income attributable to the company does not mirror this steady climb. For example, between 2022 and 2024, net income decreased from 5,039 million USD to 3,676 million USD despite a general increase in sales volume over the same span. This divergence suggests that internal cost pressures or external economic factors impacted the bottom line more significantly than top-line growth could offset.
Profitability Recovery and Stabilization
The period between 2024 and 2026 indicates a trend toward stabilization. Net income recovered from its 2024 trough of 3,676 million USD to reach 4,801 million USD by 2026. The corresponding stabilization of the net profit margin between 13.20% and 13.90% suggests a return to more sustainable operational efficiency as the company scaled its revenue toward the 36 billion USD mark.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Return on Equity (ROE)

Medtronic PLC, ROE calculation, comparison to benchmarks

Microsoft Excel
Apr 24, 2026 Apr 25, 2025 Apr 26, 2024 Apr 28, 2023 Apr 29, 2022 Apr 30, 2021
Selected Financial Data (US$ in millions)
Net income attributable to Medtronic 4,801 4,662 3,676 3,758 5,039 3,606
Shareholders’ equity 49,463 48,024 50,214 51,483 52,551 51,428
Profitability Ratio
ROE1 9.71% 9.71% 7.32% 7.30% 9.59% 7.01%
Benchmarks
ROE, Competitors2
Abbott Laboratories — 12.51% 28.12% 14.83% 18.90% 19.75%
Elevance Health Inc. — 12.90% 14.47% 15.23% 16.59% 16.93%
Intuitive Surgical Inc. — 16.02% 14.13% 13.51% 11.98% 14.32%
UnitedHealth Group Inc. — 12.81% 15.55% 25.22% 25.87% 24.09%
ROE, Sector
Health Care Equipment & Services — 12.41% 16.02% 17.13% 18.40% 17.28%
ROE, Industry
Health Care — 21.47% 15.74% 19.40% 24.82% 25.44%

Based on: 10-K (reporting date: 2026-04-24), 10-K (reporting date: 2025-04-25), 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30).

1 2026 Calculation
ROE = 100 × Net income attributable to Medtronic ÷ Shareholders’ equity
= 100 × 4,801 ÷ 49,463 = 9.71%

2 Click competitor name to see calculations.


An analysis of the financial performance from 2021 to 2026 reveals a fluctuating yet generally improving trend in profitability relative to shareholder equity.

Return on Equity (ROE) Volatility
The ROE exhibited notable variability over the six-year period. Beginning at 7.01% in 2021, the ratio surged to 9.59% in 2022 before experiencing a contraction to 7.30% in 2023 and 7.32% in 2024. A significant recovery followed, with the ROE climbing to 9.71% in 2025 and maintaining that level through 2026.
Net Income Drivers
Fluctuations in ROE closely correlate with shifts in net income. The peak in 2022 was driven by a substantial increase in net income to US$ 5,039 million. A subsequent decline in net income to US$ 3,758 million in 2023 and US$ 3,676 million in 2024 mirrored the dip in ROE. The return to higher profitability in 2025 and 2026, with net income reaching US$ 4,801 million, served as the primary catalyst for the improved return on equity.
Equity Base Influence
Shareholders' equity remained relatively stable, though a gradual decline is observable from a peak of US$ 52,551 million in 2022 to a low of US$ 48,024 million in 2025. This reduction in the equity base, occurring simultaneously with the recovery of net income in the final two periods, amplified the growth of the ROE, resulting in the peak value of 9.71% observed in 2025 and 2026.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Return on Assets (ROA)

Medtronic PLC, ROA calculation, comparison to benchmarks

Microsoft Excel
Apr 24, 2026 Apr 25, 2025 Apr 26, 2024 Apr 28, 2023 Apr 29, 2022 Apr 30, 2021
Selected Financial Data (US$ in millions)
Net income attributable to Medtronic 4,801 4,662 3,676 3,758 5,039 3,606
Total assets 93,028 91,680 89,981 90,948 90,981 93,083
Profitability Ratio
ROA1 5.16% 5.09% 4.09% 4.13% 5.54% 3.87%
Benchmarks
ROA, Competitors2
Abbott Laboratories — 7.52% 16.46% 7.82% 9.31% 9.40%
Elevance Health Inc. — 4.66% 5.12% 5.50% 5.86% 6.26%
Intuitive Surgical Inc. — 13.96% 12.39% 11.64% 10.19% 12.58%
UnitedHealth Group Inc. — 3.89% 4.83% 8.18% 8.19% 8.15%
ROA, Sector
Health Care Equipment & Services — 5.04% 6.57% 7.05% 7.49% 7.28%
ROA, Industry
Health Care — 7.89% 5.73% 7.19% 9.66% 9.46%

Based on: 10-K (reporting date: 2026-04-24), 10-K (reporting date: 2025-04-25), 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30).

1 2026 Calculation
ROA = 100 × Net income attributable to Medtronic ÷ Total assets
= 100 × 4,801 ÷ 93,028 = 5.16%

2 Click competitor name to see calculations.


The return on assets (ROA) demonstrates a fluctuating but generally positive trajectory over the six-year period, beginning at 3.87% in 2021 and concluding at 5.16% in 2026. The volatility observed in this ratio is primarily driven by variations in net income, as the total asset base remained relatively stable throughout the analyzed timeframe.

Net Income Trends
Net income exhibited significant volatility, peaking at US$ 5,039 million in 2022 before experiencing a decline to US$ 3,676 million by 2024. A subsequent recovery is evident in the final two years, with earnings rising to US$ 4,801 million in 2026.
Asset Base Consistency
Total assets remained remarkably consistent, fluctuating within a narrow band between US$ 89,981 million and US$ 93,083 million. This stability indicates that the changes in ROA were not the result of significant balance sheet expansion or contraction, but were instead dictated by the company's ability to generate profit from its existing resource base.
ROA Performance and Efficiency
The ROA reached a peak of 5.54% in 2022, correlating with the highest reported net income. Despite a mid-period dip to approximately 4.1% between 2023 and 2024, a recovery trend emerged, with the ratio climbing to 5.09% in 2025 and 5.16% in 2026. This upward movement in the latter years suggests an improvement in operational efficiency and a strengthened capacity to convert assets into net earnings.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?